IP Library › Granted Patent US 12,281,149
Granted Patent B2
US 12,281,149 · App. 17/744,540 · Granted Apr 22, 2025

Modulators of G-protein coupled receptors

Inventors: Daniel Erlanson (San Francisco, CA); Raymond V. Fucini (San Bruno, CA); Stig Hansen (Kensington, CA); Jeff Iwig (Berkeley, CA); Shyam Krishnan (Novato, CA); Enrique Moya (Berkeley, CA); Steven Sethofer (Emeryville, CA)
Assignee: Carmot Therapeutics, Inc.
C07K14/605A61K38/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,281,149
App. No.
17/744,540
Granted
Apr 22, 2025
Kind
B2
Abstract

This disclosure features chemical entities (e.g., a compound or a pharmaceutically acceptable salt) that modulate (e.g., agonize or partially agonize or antagonize) glucagon-like peptide-1 receptor (“GLP-1R”) and/or the gastric inhibitory polypeptide receptor (“GIPR”). The chemical entities are useful, e.g., for treating a disease, disorder, or condition in which modulation (e.g., agonism, partial agonism or antagonism) of GLP-1R and/or GIPR activities is beneficial for the treatment or prevention of the underlying pathology and/or symptoms and/or progression of the disease, disorder, or condition. In some embodiments, modulation results in enhancement of (e.g., increases) existing levels (e.g., normal or below normal levels) of GLP-1R and/or GIPR activity (e.g., signaling). In some embodiments, the chemical entities described herein further modulate (e.g., attenuate, uncouple) β-arrestin signaling relative to what is observed with the native ligand. This disclosure also features compositions as well as other methods of using and making the said chemical entities.

Claims (11)

1. A compound, or pharmaceutically acceptable salt thereof, wherein the compound is selected from the group consisting of:

2. A compound, or pharmaceutically acceptable salt thereof, wherein the compound is selected form the group consisting of:

3. The compound of claim 2 , wherein the compound is:

4. The compound of claim 2 , wherein the compound is:

5. The compound of claim 2 , wherein the compound is:

6. The compound of claim 2 , wherein the compound is:

7. The compound of claim 2 , wherein the compound is:

8. The compound of claim 2 , wherein the compound is:

9. The compound of claim 2 , wherein the compound is:

10. The compound of claim 2 , wherein the compound is:

11. A pharmaceutical composition comprising the compound, or pharmaceutically acceptable salt thereof, of claim 1 or 2 and one or more pharmaceutically acceptable excipients.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 17, 2022
From: ERLANSON, DANIEL; FUCINI, RAYMOND V.; HANSEN, STIG; IWIG, JEFF; KRISHNAN, SHYAM; MOYA, ENRIQUE; SETHOFER, STEVEN
To: CARMOT THERAPEUTICS, INC.
Reel/Frame 060829/0201 →
Continuity (2)
Provisional Application 63188342 · May 13, 2021
Related Publication 20230151074A1 · May 18, 2023
References Cited (127)
US 8163757B2 · Matthews et al. · 2012 [cited by applicant]
US 8372837B2 · Wacker et al. · 2013 [cited by applicant]
US 8551946B2 · Dimarchi et al. · 2013 [cited by applicant]
US 8975223B2 · Vignati et al. · 2015 [cited by applicant]
US 9062124B2 · Dimarchi et al. · 2015 [cited by applicant]
US 9474780B2 · Bokvist et al. · 2016 [cited by applicant]
US 9487571B2 · Dimarchi et al. · 2016 [cited by applicant]
US 9764004B2 · Alsina-Fernandez et al. · 2017 [cited by applicant]
US 9884091B2 · Hölscher et al. · 2018 [cited by applicant]
US 9884093B2 · Alsina-Fernandez et al. · 2018 [cited by applicant]
US 11220534B2 · Hölscher et al. · 2022 [cited by applicant]
US 20060275288A1 · Grihalde et al. · 2006 [cited by applicant]
US 20100190750A1 · Chu et al. · 2010 [cited by applicant]
US 20120021979A1 · Galli et al. · 2012 [cited by applicant]
US 20120148586A1 · Chou et al. · 2012 [cited by applicant]
US 20130040884A1 · Lau et al. · 2013 [cited by applicant]
US 20150322130A1 · Dimarchi et al. · 2015 [cited by applicant]
US 20150352219A1 · Anderson et al. · 2015 [cited by applicant]
US 20160175400A1 · Vignati et al. · 2016 [cited by applicant]
US 20170095554A1 · Brimble et al. · 2017 [cited by applicant]
US 20170326233A1 · Demeule et al. · 2017 [cited by applicant]
US 20220033457A1 · Hölscher et al. · 2022 [cited by applicant]
US 20220135639A1 · Coffin et al. · 2022 [cited by applicant]
US 20220251163A1 · Zhao et al. · 2022 [cited by applicant]
US 20220298214A1 · Chen et al. · 2022 [cited by applicant]
US 20230241178A1 · Thennati et al. · 2023 [cited by applicant]
CN 105219802A2 · 2016 [cited by applicant]
EP 1883419A2 · 2008 [cited by applicant]
EP 2300035B1 · 2015 [cited by applicant]
EP 2952202B1 · 2017 [cited by applicant]
EP 3242887B1 · 2019 [cited by applicant]
EP 3548061B1 · 2020 [cited by applicant]
GB 2551945A · 2018 [cited by applicant]
WO WO1997010224A1 · 1997 [cited by applicant]
WO WO1999043707A1 · 1999 [cited by applicant]
WO WO2000034331A2 · 2000 [cited by applicant]
WO WO2001014371A1 · 2001 [cited by applicant]
WO WO2001014372A1 · 2001 [cited by applicant]
WO WO2001017568A2 · 2001 [cited by applicant]
WO WO2001062765A2 · 2001 [cited by applicant]
WO WO2002006234A1 · 2002 [cited by applicant]
WO WO2004039365A1 · 2004 [cited by applicant]
WO WO2004041266A1 · 2004 [cited by applicant]
WO WO2004048363A1 · 2004 [cited by applicant]
WO WO2004067548A2 · 2004 [cited by applicant]
WO WO2004106276A1 · 2004 [cited by applicant]
WO WO2005030740A1 · 2005 [cited by applicant]
WO WO2005058823A1 · 2005 [cited by applicant]
WO WO2005063725A1 · 2005 [cited by applicant]
WO WO2005063729A1 · 2005 [cited by applicant]
WO WO2005087710A1 · 2005 [cited by applicant]
WO WO2005095338A1 · 2005 [cited by applicant]
WO WO2005113504A1 · 2005 [cited by applicant]
WO WO2006112549A1 · 2006 [cited by applicant]
WO WO2006121860A2 · 2006 [cited by applicant]
WO WO2007013689A1 · 2007 [cited by applicant]
WO WO2007013694A1 · 2007 [cited by applicant]
WO WO2007018314A2 · 2007 [cited by applicant]
WO WO2007028135A2 · 2007 [cited by applicant]
WO WO2008001931A2 · 2008 [cited by applicant]
WO WO2008021560A2 · 2008 [cited by applicant]
WO WO2008047821A1 · 2008 [cited by applicant]
WO WO2008050821A1 · 2008 [cited by applicant]
WO WO2008093639A1 · 2008 [cited by applicant]
WO WO2008099794A1 · 2008 [cited by applicant]
WO WO2008136428A1 · 2008 [cited by applicant]
WO WO2008156757A1 · 2008 [cited by applicant]
WO 2009115469A1 · 2009 [cited by applicant]
WO WO2010011439A2 · 2010 [cited by applicant]
WO WO2011044212A1 · 2011 [cited by applicant]
WO WO2011094337A1 · 2011 [cited by applicant]
WO WO2011143365A1 · 2011 [cited by applicant]
WO WO2012088379A2 · 2012 [cited by applicant]
WO WO2012158965A2 · 2012 [cited by applicant]
WO WO2012167744A1 · 2012 [cited by applicant]
WO WO2013148579A1 · 2013 [cited by applicant]
WO WO2014074218A1 · 2014 [cited by applicant]
WO WO2014165240A1 · 2014 [cited by applicant]
WO WO2015031268A1 · 2015 [cited by applicant]
WO WO2016131893A1 · 2016 [cited by applicant]
WO WO2018104718A1 · 2018 [cited by applicant]
WO WO2019183577A1 · 2019 [cited by applicant]
WO WO2020159949A1 · 2020 [cited by applicant]
WO WO2022079639A1 · 2022 [cited by applicant]
WO WO2022080986A1 · 2022 [cited by applicant]
WO WO2022121666A1 · 2022 [cited by applicant]
WO WO2022139538A1 · 2022 [cited by applicant]
WO WO2022241287A2 · 2022 [cited by examiner]
WO WO2023028466A1 · 2023 [cited by applicant]
WO WO2023030444A1 · 2023 [cited by applicant]
WO WO2023089594A1 · 2023 [cited by applicant]
Lafferty et al. “Proglucagon-Derived Peptides as Therapeutics” Frontiers in Endocrinology 12:689678. (Year: 2021). [cited by examiner]
American Diabetes Association's (ADA), “Standards of Medical Care in Diabetes-2022 Abridged for Primary Care Providers,” [cited by applicant]
Angulo et al., “Non-alcoholic fatty liver disease,” [cited by applicant]
Azimova et al., “Cardiovascular Safety Profile of Currently Available Diabetic Drugs,” [cited by applicant]
Battelino et al., “Continuous glucose monitoring and metrics for clinical trials: an international consensus statement,” [cited by applicant]
Bonnet et al., “Structural studies in aqueous solution of new binuclear lanthanide luminescent peptide conjugates,” [cited by applicant]
Bonnet et al., “Luminescent lanthanide-binding peptides: sensitising the excited states of Eu(iii) and Tb(iii) with a 1,8-naphthalimide-based antenna,” [cited by applicant]
Chitturi et al., “NASH and insulin resistance: Insulin hypersecretion and specific association with the insulin resistance syndrome,” [cited by applicant]
Choi et al., “Highly efficient and fast pre-activation cyclization of the long peptide: Succinimidyl ester-amine reaction revisited,” [cited by applicant]
Chopra et al., “Versatile cyclic templates for assembly of axially oriented ligands,” [cited by applicant]
Clarke et al., “Reduced awareness of hypoglycemia in adults with IDDM. A prospective study of hypoglycemic frequency and associated symptoms,” [cited by applicant]
Deacon et al., “Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo,” [cited by applicant]
Demoin et al., “Monooxorhenium (V) complexes with 222-N2S2 MAMA ligands for bifunctional chelator agents: Syntheses and preliminary in vivo evaluation,” [cited by applicant]
Elduque et al., “Straightforward synthesis of cyclic and bicyclic peptides,” [cited by applicant]
Faull et al., “Revised primary structures of rat pituitary gamma-lipotrophin and beta-endorphin,” [cited by applicant]
Finan et al., “Unimolecular dual incretins maximize metabolic benefits in rodents, monkeys, and humans,” [cited by applicant]
Gregory et al., “latrogenic hyperinsulinemia, not hyperglycemia, drives insulin resistance in Type 1 Diabetes as revealed by comparison with GCK-MODY (MODY2),” [cited by applicant]
Gupta et al., “Whole-virus screening to develop synbodies for the influenza virus,” [cited by applicant]
Guy et al., “De novo helical peptides as target sequences for a specific, fluorogenic protein labelling strategy,” [cited by applicant]
Hsia et al., “An update on sodium-glucose co-transporter-2 inhibitors for the treatment of diabetes mellitus,” [cited by applicant]
Khaodhiar et al., “Treating diabetes and prediabetes by focusing on obesity management,” [cited by applicant]
Kim et al., “Targeting of secretory proteins as a therapeutic strategy for treatment of nonalcoholic steatohepatitis (NASH),” [cited by applicant]
Kitabchi et al., “Hyperglycemic crises in adult patients with diabetes,” [cited by applicant]
Lisse et al., “Monofunctional stealth nanoparticle for unbiased single molecule tracking inside living cells,” [cited by applicant]
Lisse et al., “Supplementary information and results: Monofunctional Stealth Nanoparticle for Unbiased Single Molecule Tracking Inside Living Cells,” [cited by applicant]
Marín-Peñalver et al., “Update on the treatment of type 2 diabetes mellitus,” [cited by applicant]
Moshitzky et al., “Determination of locust AKH-I by radioimmunoassay and the identification of an AKH-like factor in the locust brain,” [cited by applicant]
Nacheva et al., “Fluorescent properties and resonance energy transfer of 3,4-bis(2,4-difluorophenyl)-maleimide,” [cited by applicant]
Sakai et al., “Self-assembly: Formation of functionalized nanowires by control of self-assembly using multiple modified amyloid peptides,” [cited by applicant]
Schauer et al., “Insulin resistance, defective insulin-mediated fatty acid suppression, and coronary artery calcification in subjects with and without type 1 diabetes: The CACTI study,” [cited by applicant]
Sieno et al., “Glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1: Incretin actions beyond the pancreas,” [cited by applicant]
Shirmardi et al., “Preclinical evaluation of a new bombesin analog for imaging of gastrin-releasing peptide receptors,” [cited by applicant]
Skelly et al., “Finding on liver biopsy to investigate abnormal liver function tests in the absence of diagnostic serology,” 2001, [cited by applicant]
Van Der Schueren et al., “Obesity in people living with type 1 diabetes,” [cited by applicant]
Extended Search Report in European Application No. 19772275.4, dated Apr. 7, 2022, 11 pages. [cited by applicant]
Written Opinion and Search Report in Singaporean Application No. 11202009338S, dated Mar. 15, 2022, 9 pages. [cited by applicant]